Compare ANNX & SCZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | SCZM |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | N/A | 455 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.3M | 847.1M |
| IPO Year | 2020 | N/A |
| Metric | ANNX | SCZM |
|---|---|---|
| Price | $3.96 | $8.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $15.43 | ★ $16.97 |
| AVG Volume (30 Days) | ★ 3.0M | 394.8K |
| Earning Date | 11-09-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $49.99 |
| Revenue Next Year | N/A | $12.57 |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $5.61 |
| 52 Week High | $7.18 | $17.65 |
| Indicator | ANNX | SCZM |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 48.89 |
| Support Level | $3.71 | $8.55 |
| Resistance Level | $4.37 | $9.05 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 45.33 | 47.62 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.